Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 13/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.64 |
| ▸ | PGR | P06401 | 4/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | SHBG | P04278 | 2/20 | 0.64 |
| ▸ | AR | P10275 | 2/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | IL6 | P05231 | 1/20 | 0.59 |
| ▸ | GLUL | P15104 | 1/20 | 0.59 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.59 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14931695 | 1.00 | HIF1A (0.64) | HIF1AHSD17B10NR3C1PGRSERPINA6 | |
| SCHEMBL6001323 | 0.99 | HIF1A (0.65) | HIF1AHSD17B10NR3C1PGRSERPINA6 | |
| SCHEMBL27571456 | 0.97 | HIF1A (0.61) | HIF1AHSD17B10NR3C1PGRSERPINA6 | |
| SCHEMBL27941428 | 0.97 | HIF1A (0.61) | HIF1AHSD17B10NR3C1PGRSERPINA6 | |
| SCHEMBL1301994 | 0.96 | HIF1A (0.62) | HIF1AHSD17B10NR3C1PGRSERPINA6 | |
| SCHEMBL1535104 | 0.96 | HIF1A (0.63) | HIF1AHSD17B10NR3C1PGRSERPINA6 | |
| SCHEMBL141828 | 0.95 | HIF1A (0.62) | HIF1AHSD17B10NR3C1PGRSERPINA6 | |
| SCHEMBL28809123 | 0.95 | HIF1A (0.66) | HIF1AHSD17B10NR3C1PGRSERPINA6 | |
| SCHEMBL41085 | 0.94 | HIF1A (0.63) | HIF1AHSD17B10NR3C1PGRSERPINA6 | |
| SCHEMBL141360 | 0.94 | HIF1A (0.61) | HIF1AHSD17B10NR3C1PGRSERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 504 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526968-A2 | Nogo receptor antagonists | Biogen Idec MA Inc. (US) | 2012-11-28 | — | — | EP | claimed |
| WO-2007089601-A9 | NOGO RECEPTOR ANTAGONISTS | BIOGEN IDEC INC (US) | 2008-12-18 | — | — | WO | claimed |
| EP-1981902-A2 | NOGO RECEPTOR ANTAGONISTS | Biogen Idec MA Inc. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007089601-A2 | NOGO RECEPTOR ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2007-08-09 | — | — | WO | claimed |
| EP-1740187-A1 | MACULAR EDEMA PATIENT SELECTION METHOD AND TREATMENT WITH EYE IMPLANT COMPRISING A STEROID | Bausch & Lomb Incorporated (US) | 2007-01-10 | — | — | EP | claimed |
| WO-2005099717-A1 | MACULAR EDEMA PATIENT SELECTION METHOD AND TREATMENT WITH EYE IMPLANT COMPRISING A STEROID | BAUSCH & LOMB INCORPORATED (US) | 2005-10-27 | — | — | WO | claimed |
| US-20050226814-A1 | Diagnostic method and kit for implantation of a sustained release drug-delivery implant with a steroid | BAUSCH & LOMB INCORPORATED | 2005-10-13 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0786999-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1999-01-20 | — | — | EP | claimed |
| EP-0792371-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| CN-1137748-A | Gas used as local and subcutaneous transmission carrier and microspheres filled with gas precursor | IMARX PHARMACEUTICAL CORP (US) | 1996-12-11 | — | — | CN | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |
| US-20250304667-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN INC (US) | 2025-10-02 | — | — | US | disclosed |
| CN-114716544-B | Complement component C5 antibodies | 阿勒根公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240294652-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN K-A, INC. | 2024-09-05 | — | — | US | disclosed |
| US-20240279317-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN INC (US) | 2024-08-22 | — | — | US | disclosed |
| US-11858999-B2 | IL-17 receptor A antigen binding proteins | AMGEN K-A, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230124150-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN, INC. | 2023-04-20 | — | — | US | disclosed |
| CN-114480253-B | Culture medium for directional induced differentiation of pluripotent stem cells into hepatocytes, culture method and application | 深圳市三启生物技术有限公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-115515634-A | Methods of treating Crohn's disease with anti-IL 23 specific antibodies | 詹森生物科技公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-115427444-A | Safe and effective methods for treating ulcerative colitis with anti-IL 12/IL23 antibodies | 詹森生物科技公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-114716544-A | Complement component C5 antibody | 阿勒根公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4008726-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN, INC. (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-114480253-A | Culture medium for directional induced differentiation of pluripotent stem cells into hepatocytes, culture method and application | 深圳市三启生物技术有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220047773-A1 | SELF-ELIMINATING COATINGS | INTERFACE BIOLOGICS, INC. (CA) | 2022-02-17 | — | — | US | disclosed |
| US-20220040385-A1 | LOCAL DELIVERY OF DRUGS FROM SELF ASSEMBLED COATINGS | INTERFACE BIOLOGICS, INC. (CA) | 2022-02-10 | — | — | US | disclosed |
| CN-107207585-B | Complement component C5 antibody | 阿勒根公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3165539-B1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN K A INC (US) | 2021-12-08 | — | — | EP | disclosed |
| US-11180564-B2 | IL-17 Receptor A antigen binding proteins | AMGEN K-A, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210101965-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | XENCOR, INC. | 2021-04-08 | — | — | US | disclosed |
| CN-106456751-B | Method for treating nail and scalp psoriasis | 安姆根K-A有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20200362045-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN K-A, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200317762-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN INC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10752678-B2 | Complement component C5 antibodies | ALLERGAN, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200197310-A1 | Technology for Preparation of Macromolecular Microspheres | NEXBIO, INC. | 2020-06-25 | — | — | US | disclosed |
| EP-3107935-B1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN INC (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3653643-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN, INC. (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10604563-B2 | Nucleic acids encoding anti-complement Factor Bb antibodies | ALLERGAN, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10583086-B2 | Technology for preparation of macromolecular microspheres | ANSUN BIOPHARMA, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| CN-110724691-A | Complement factor Bb antibodies | 阿勒根公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-106232624-B | Complement factor Bb antibodies | 阿勒根公司 | 2020-01-21 | — | — | CN | disclosed |
| US-20190298889-A1 | LOCAL DELIVERY OF DRUGS FROM SELF ASSEMBLED COATINGS | INTERFACE BIOLOGICS, INC. (CA) | 2019-10-03 | — | — | US | disclosed |
| EP-3126392-B1 | METHODS OF TREATING NAIL AND SCALP PSORIASIS | KIRIN AMGEN INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20190262426-A1 | Hydrogel-Linked IL-1ra Prodrug | ASCENDIS PHARMA A/S (DK) | 2019-08-29 | — | — | US | disclosed |
| EP-1996710-B1 | RIFAXIMIN ANTI-RECTAL DYSFUNCTION PREPARATION | SALIX PHARMACEUTICALS INC (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3054982-B1 | HYDROGEL-LINKED IL-1RA PRODRUG | ASCENDIS PHARMA AS (DK) | 2019-05-01 | — | — | EP | disclosed |
| US-10231938-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20190071492-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN INC (US) | 2019-03-07 | — | — | US | disclosed |
| US-10208122-B2 | IL-17 receptor A antigen binding proteins | AMGEN K-A, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10195311-B2 | Local delivery of drugs from self assembled coatings | INTERFACE BIOLOGICS, INC. (CA) | 2019-02-05 | — | — | US | disclosed |
| US-10093724-B2 | Methods of treating a complement associated eye condition by administering complement factor Bb antibodies | ALLERGAN, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180222969-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | XENCOR, INC. | 2018-08-09 | — | — | US | disclosed |
| US-10039864-B2 | Oligofluorinated cross-linked polymers and uses thereof | INTERFACE BIOLOGICS, INC. (CA) | 2018-08-07 | — | — | US | disclosed |
| US-9932395-B2 | Nucleic acids encoding complement component C5 antibodies | ALLERGAN, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180071219-A1 | Technology for Preparation of Macromolecular Microspheres | NEXBIO, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180057576-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180042996-A1 | Hydrogel-Linked IL-1ra Prodrug | ASCENDIS PHARMA OSTEOARTHRITIS DIVISION A/S (DK) | 2018-02-15 | — | — | US | disclosed |
| US-20180028449-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2018-02-01 | — | — | US | disclosed |
| US-20180028721-A1 | SELF-ELIMINATING COATINGS | INTERFACE BIOLOGICS, INC. (CA) | 2018-02-01 | — | — | US | disclosed |
| EP-2203498-B1 | OLIGOFLUORINATED CROSS-LINKED POLYMERS AND USES THEREOF | INTERFACE BIOLOGICS INC (CA) | 2017-12-06 | — | — | EP | disclosed |
| US-20170340781-A1 | OLIGOFLUORINATED CROSS-LINKED POLYMERS AND USES THEREOF | Evonik Canada Inc. (CA) | 2017-11-30 | — | — | US | disclosed |
| US-20170306007-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9796776-B2 | Complement factor Bb antibodies | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9701743-B2 | Complement component C5 antibodies | ALLERGAN, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170174772-A1 | METHODS OF TREATING NAIL AND SCALP PSORIASIS | KIRIN-AMGEN, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9682043-B2 | Method of preparation of mixed phase co-crystals with active agents | MEDCRYSTALFORMS, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| EP-3165539-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | Kirin-Amgen, Inc. (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20170114140-A1 | IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF | KIRIN-AMGEN INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170079920-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2017-03-23 | — | — | US | disclosed |
| EP-2487188-B1 | IL-17 receptor A antigen binding proteins | KIRIN-AMGEN INC (US) | 2017-03-08 | — | — | EP | disclosed |
| CN-106456751-A | Methods of treating nail and scalp psoriasis | 麒麟-安姆根有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-3126392-A1 | METHODS OF TREATING NAIL AND SCALP PSORIASIS | Kirin-Amgen, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-2002846-B1 | Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases | AMGEN INC (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-3110845-A1 | COMPLEMENT FACTOR BB ANTIBODIES | ALLERGAN, INC. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-3107935-A2 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN, INC. (US) | 2016-12-28 | — | — | EP | disclosed |
| CN-106232624-A | Complement factor Bb antibodies | 阿勒根公司 | 2016-12-14 | — | — | CN | disclosed |
| EP-2214748-B1 | SELF-ELIMINATING COATINGS | INTERFACE BIOLOGICS INC (CA) | 2016-12-07 | — | — | EP | disclosed |
| EP-2518085-B1 | IL-17 receptor A antigen binding proteins | KIRIN-AMGEN INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160251443-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160235675-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2016-08-18 | — | — | US | disclosed |
| EP-3054982-A1 | HYDROGEL-LINKED IL-1RA PRODRUG | Ascendis Pharma Osteoarthritis Division A/S (DK) | 2016-08-17 | — | — | EP | disclosed |
| US-20160208004-A1 | IL-17RA-IL-17RB Antagonists and Uses Thereof | AMGEN INC (US) | 2016-07-21 | — | — | US | disclosed |
| EP-1807033-B1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMA (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160159878-A1 | NOGO Receptor Antagonists | BIOGEN MA INC (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159914-A1 | IL-17 RECEPTOR A IS REQUIRED FOR IL-17C BIOLOGY | AMGEN INC (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160128949-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160008391-A1 | GALACTOSAMINOGALACTAN COMPRISING alpha-1-4 LINKED GALACTOSE AND alpha-1-4 LINKED N-ACETYLGALACTOSAMINE FOR USE IN THE TREATMENT OF AT LEAST ONE INFLAMMATORY DISEASE | PASTEUR INSTITUT (FR) | 2016-01-14 | — | — | US | disclosed |
| EP-2964196-A1 | PHARMACEUTICAL COMPOSITIONS FOR RECTAL ADMINISTRATION | Cipla Limited (IN) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002278-A1 | Pharmaceutical Compositions for Rectal Administration | CIPLA LIMITED (MH) | 2016-01-07 | — | — | US | disclosed |
| US-9228015-B2 | Nogo receptor antagonists and methods of increasing neurite outgrowth | BIOGEN IDEC MA INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150359746-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2015-12-17 | — | — | US | disclosed |
| CN-105142612-A | Pharmaceutical compositions for rectal administration | CIPLA LTD | 2015-12-09 | — | — | CN | disclosed |
| EP-2945638-A1 | GALACTOSAMINOGALACTAN COMPRISING 1-4 LINKED GALACTOSE AND 1-4 LINKED N-ACETYLGALACTOSAMINE FOR USE IN THE TREATMENT OF AT LEAST ONE INFLAMMATORY DISEASE | Institut Pasteur (FR) | 2015-11-25 | — | — | EP | disclosed |
| US-20150290134-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | NEXBIO, INC. | 2015-10-15 | — | — | US | disclosed |
| US-9155712-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| WO-2015153144-A1 | METHODS OF TREATING NAIL AND SCALP PSORIASIS | KIRIN-AMGEN, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150283304-A1 | LOCAL DELIVERY OF DRUGS FROM SELF ASSEMBLED COATINGS | INTERFACE BIOLOGICS, INC. (CA) | 2015-10-08 | — | — | US | disclosed |
| WO-2015130826-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150239966-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | XENCOR, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239987-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN, INC. | 2015-08-27 | — | — | US | disclosed |
| WO-2015127134-A2 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-9096673-B2 | IL-17 receptor A antigen binding proteins | KIRIN-AMGEN, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| EP-1981902-B1 | NOGO RECEPTOR ANTAGONISTS | BIOGEN MA INC (US) | 2015-07-29 | — | — | EP | disclosed |
| CN-102497864-B | Sigma ligands for the prevention or treatment of pain induced by chemotherapy | ESTEVE LABOR DR | 2015-07-22 | — | — | CN | disclosed |
| US-20150196488-A1 | Topical Foam Composition | CIPLA LIMITED (IN) | 2015-07-16 | — | — | US | disclosed |
| CN-102985089-B | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | ESTEVE LABOR DR | 2015-07-15 | — | — | CN | disclosed |
| CN-104758253-A | Technology for preparation of macromolecular microspheres | NEXBIO INC | 2015-07-08 | — | — | CN | disclosed |
| US-20150157578-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| CN-103214576-B | IL-17 receptor A antigen binding proteins | AMGEN INC | 2015-06-03 | — | — | CN | disclosed |
| WO-2015052154-A1 | HYDROGEL-LINKED IL-1RA PRODRUG | ASCENDIS PHARMA OSTEOARTHRITIS DIVISION A/S (DK) | 2015-04-16 | — | — | WO | disclosed |
| US-8987292-B2 | Rifaximin anti-rectal dysfunction preparation | SALIX PHARMACEUTICALS, LTD. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8962697-B2 | Bioreponsive polymers | INTERFACE BIOLOGICS INC. (CA) | 2015-02-24 | — | — | US | disclosed |
| US-20150050713-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2015-02-19 | — | — | US | disclosed |
| EP-2076541-B1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | KIRIN AMGEN INC (US) | 2015-02-18 | — | — | EP | disclosed |
| US-20140356355-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN INC (US) | 2014-12-04 | — | — | US | disclosed |
| US-8900603-B2 | Local delivery of drugs from self assembled coatings | INTERFACE BIOLOGICS, INC. (CA) | 2014-12-02 | — | — | US | disclosed |
| CN-104151428-A | IL-17RA-IL-17RB antagonists and uses thereof | AMGEN INC | 2014-11-19 | — | — | CN | disclosed |
| US-20140322238-A1 | IL-17RA-IL-17RB Antagonists and Uses Thereof | AMGEN INC. (US) | 2014-10-30 | — | — | US | disclosed |
| WO-2014135891-A1 | PHARMACEUTICAL COMPOSITIONS FOR RECTAL ADMINISTRATION | CIPLA LIMITED (IN) | 2014-09-12 | — | — | WO | disclosed |
| US-8815281-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140234330-A1 | IL-17 RECEPTOR A IS REQUIRED FOR IL-17C BIOLOGY | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140227266-A1 | NOGO Receptor Antagonists | BIOGEN IDEC MA INC. (US) | 2014-08-14 | — | — | US | disclosed |
| EP-2759299-A1 | Galactosaminogalactan comprising alpha 1-4 linked galactose and alpha 1-4 linked N-acetylgalactosamine for use in the treatment of at least one inflammatory disease | INSTITUT PASTEUR (FR) | 2014-07-30 | — | — | EP | disclosed |
| US-8790648-B2 | Methods of treating psoriasis using IL-17 receptor A antibodies | AMGEN INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8784893-B2 | Polymer formulations for delivery of bioactive agents | CARBYLAN THERAPEUTICS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2014108570-A1 | GALACTOSAMINOGALACTAN COMPRISING α1-4 LINKED GALACTOSE AND α1-4 LINKED N-ACETYLGALACTOSAMINE FOR USE IN THE TREATMENT OF AT LEAST ONE INFLAMMATORY DISEASE | INSTITUT PASTEUR (FR) | 2014-07-17 | — | — | WO | disclosed |
| CN-102037017-B | IL-17RA-IL-17RB antagonists and uses thereof | AMGEN INC | 2014-07-09 | — | — | CN | disclosed |
| US-20140134150-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | ANSUN BIOPHARMA, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| CN-103784408-A | Technology for the preparation of microparticles | ANSUN BIOPHARMA INC | 2014-05-14 | — | — | CN | disclosed |
| US-20140099696-A1 | Technology for the Preparation of Microparticles | ANSUN BIOPHARMA, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8669345-B2 | Nogo receptor antagonists | BIOGEN IDEC MA INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20140037635-A1 | METHODS OF TREATMENT USING IL-17E ANTAGONISTS | AMGEN INC. (US) | 2014-02-06 | — | — | US | disclosed |
| CN-101541833-B | Il-17 receptor a antigen binding proteins | KIRIN AMGEN INC | 2014-01-29 | — | — | CN | disclosed |
| US-8623419-B2 | Technology for preparation of macromolecular microspheres | ANSUN BIOPHARMA, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130315988-A1 | Pharmaceutical Composition | CIPLA LIMITED (IN) | 2013-11-28 | — | — | US | disclosed |
| US-20130315998-A1 | Topical Foam Composition | CIPLA LIMITED (IN) | 2013-11-28 | — | — | US | disclosed |
| EP-1294765-B1 | Use of an antibody specific for an IL-17 like polypeptide | AMGEN INC (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8591941-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20130302886-A1 | Pre-Ligand assembly domain of the IL-17 receptor | RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2013-11-14 | — | — | US | disclosed |
| US-8574604-B2 | Methods and compositions for the delivery of biologically active agents | INTERFACE BIOLOGICS, INC. (CA) | 2013-11-05 | — | — | US | disclosed |
| US-8545842-B2 | Polynucleotides encoding IL-17 receptor A antigen binding proteins | KIRIN-AMGEN, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130202654-A1 | Topical Foam Composition | CIPLA LIMITED (IN) | 2013-08-08 | — | — | US | disclosed |
| EP-2616044-A1 | PHARMACEUTICAL COMPOSITION | Cilpa Limited (IN) | 2013-07-24 | — | — | EP | disclosed |
| EP-2401275-B1 | NAPHTHYRIDINE DERIVATIVES HAVING BRONCHODILATING ACTIVITY | RESPIRATORIUS AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| CN-103214576-A | IL-17 receptor A antigen binding proteins | AMGEN INC | 2013-07-24 | — | — | CN | disclosed |
| CN-103221032-A | Pharmaceutical composition | CIPLA LTD | 2013-07-24 | — | — | CN | disclosed |
| US-8460647-B2 | Pre-ligand assembly domain of the IL-17 receptor | AMGEN INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130142834-A1 | LOCAL DELIVERY OF DRUGS FROM SELF ASSEMBLED COATINGS | Interface Biiologics, Inc. (CA) | 2013-06-06 | — | — | US | disclosed |
| US-20130142799-A1 | Angiopoietin-2 Specific Binding Agents | AMGEN, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8445016-B2 | Grafted polymers and uses thereof | INTERFACE BIOLOGICS, INC. (CA) | 2013-05-21 | — | — | US | disclosed |
| US-8440176-B2 | Covalently grafted pharmaceutically active polymers | INTERFACE BIOLOGICS, INC. (CA) | 2013-05-14 | — | — | US | disclosed |
| US-8435518-B2 | Methods of using IL-17 receptor a antibodies | KIRIN-AMGEN, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8415333-B2 | Bronchodilating diazaheteroaryls | RESPIRATORIOUS AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-8414914-B2 | Compositions for mucosal delivery of agents | VIRUN, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| CN-102985089-A | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | ESTEVE LABOR DR | 2013-03-20 | — | — | CN | disclosed |
| CN-101203250-B | Methods and compositions for the delivery of biologically active agents via non-covalent interaction, and formed articles | INTERFACE BIOLOGICS INC | 2013-03-20 | — | — | CN | disclosed |
| CN-102933658-A | Local delivery of drugs from self assembled coatings | INTERFACE BIOLOGICS INC | 2013-02-13 | — | — | CN | disclosed |
| WO-2013016220-A1 | IL-17 RECEPTOR A IS REQUIRED FOR IL-17C BIOLOGY | AMGEN INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| US-20130004969-A1 | IL-17 Heteromeric Receptor Complex | AMGEN INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20120308566-A1 | USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | KIRIN-AMGEN, INC. | 2012-12-06 | — | — | US | disclosed |
| US-20120308644-A1 | Compositions for mucosal delivery of agents | ARCHIMEDES LABORATORIES, INC. | 2012-12-06 | — | — | US | disclosed |
| EP-2526968-A2 | Nogo receptor antagonists | Biogen Idec MA Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2518085-A1 | IL-17 receptor A antigen binding proteins | Kirin-Amgen, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120269881-A9 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| EP-2513225-A1 | LOCAL DELIVERY OF DRUGS FROM SELF ASSEMBLED COATINGS | Interface Biologics Inc. (CA) | 2012-10-24 | — | — | EP | disclosed |
| CN-102724960-A | Topical foam composition | CIPLA LTD | 2012-10-10 | — | — | CN | disclosed |
| CN-102724961-A | Topical foam composition | CIPLA LTD | 2012-10-10 | — | — | CN | disclosed |
| US-20120251547-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| EP-2503989-A2 | TOPICAL FOAM COMPOSITION | Cipla Limited (IN) | 2012-10-03 | — | — | EP | disclosed |
| EP-2503988-A2 | TOPICAL FOAM COMPOSITION | Cipla Limited (IN) | 2012-10-03 | — | — | EP | disclosed |
| US-8252323-B2 | Compositions for mucosal delivery of agents | VIRUN, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2488552-A1 | USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | Amgen Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2487188-A2 | IL-17 receptor A antigen binding proteins | Kirin-Amgen Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-1768647-B1 | COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENT | VIRUN INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120165762-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120157666-A1 | INTERFERON-LIKE PROTEINS AND USES THEREOF | WELCHER ANDREW (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012076832-A1 | SUPPOSITORIES COMPRISING RIFAXIMIN | CIPLA LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
| CN-102497864-A | Sigma ligands for the prevention or treatment of pain induced by chemotherapy | ESTEVE LABOR DR | 2012-06-13 | — | — | CN | disclosed |
| US-20120141590-A1 | Technology for the Preparation of Microparticles | MALAKHOV MICHAEL (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120116062-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | ANSUN BIOPHARMA, INC. | 2012-05-10 | — | — | US | disclosed |
| US-8148109-B2 | polypeptides and fusion proteins; for diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with IFN-L polypeptides | AMGEN INC. (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2012035283-A1 | PHARMACEUTICAL COMPOSITION | CIPLA LIMITED (IN) | 2012-03-22 | — | — | WO | disclosed |
| EP-1477187-B9 | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents | ALLERGAN INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8119128-B2 | Antibodies that bind urokinase-type plasminogen activator and epitopes therefor | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-02-21 | — | — | US | disclosed |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | RESPIRATORIUS AB (SE) | 2012-02-16 | — | — | US | disclosed |
| US-20120009190-A1 | IDENTIFICATION AND METHOD FOR USING THE PRE-LIGAND ASSEMBLY DOMAIN OF THE IL-17 RECEPTOR | AMGEN INC. (NY) | 2012-01-12 | — | — | US | disclosed |
| CN-101005828-B | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents | VIRUN INC | 2012-01-11 | — | — | CN | disclosed |
| EP-2401275-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | Respiratorius AB (SE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110311546-A1 | Angiopoietin-2 specific binding agents | AMGEN, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110274681-A1 | HUMAN E3ALPHA UBIQUITIN LIGASE FAMILY | AMGEN INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-1615952-B1 | METHODS OF TREATMENT OF INFLAMMATORY DISEASES USING SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 | AMGEN INC (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2361262-A1 | TETRANECTIN TRIMERI ZING MODULE TRUNCATION VARIANTS | Anaphore, Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| US-7994291-B2 | Human E3α ubiquitin ligase family | AMGEN INC. (US) | 2011-08-09 | — | — | US | disclosed |
| EP-1477187-B1 | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents | ALLERGAN INC (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20110166331-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110160438-A1 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011072398-A1 | LOCAL DELIVERY OF DRUGS FROM SELF ASSEMBLED COATINGS | INTERFACE BIOLOGICS, INC. (CA) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011061519-A2 | TOPICAL FOAM COMPOSITION | CIPLA LIMITED (IN) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011061516-A2 | TOPICAL FOAM COMPOSITION | CIPLA LIMITED (IN) | 2011-05-26 | — | — | WO | disclosed |
| US-20110117184-A1 | Compositions for mucosal delivery of agents | VIRUN, INC. | 2011-05-19 | — | — | US | disclosed |
| US-7943738-B2 | IL-17 receptor like molecules and uses thereof | AMGEN INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7939070-B2 | IL-17 receptor A antigen binding proteins | AMGEN INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20110104228-A1 | SELF-ELIMINATING COATINGS | INTERFACE BIOLOGICS, INC (CA) | 2011-05-05 | — | — | US | disclosed |
| US-20110097384-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. | 2011-04-28 | — | — | US | disclosed |
| CN-102037017-A | IL-17RA-IL-17RB antagonists and uses thereof | AMGEN INC | 2011-04-27 | — | — | CN | disclosed |
| WO-2011046958-A1 | USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20110091508-A1 | OLIGOFLUORINATED CROSS-LINKED POLYMERS AND USES THEREOF | Interface Biologics ,Inc. (CA) | 2011-04-21 | — | — | US | disclosed |
| US-20110081339-A1 | METHODS OF USING IL-17 RECEPTOR A ANTIBODIES | AMGEN INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7906140-B2 | Compositions for mucosal delivery of agents | VIRUN, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110052600-A1 | IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF | AMGEN INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110033540-A1 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | CARBYLAN THERAPEUTICS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110008841-A1 | POLYNUCLEOTIDES ENCODING IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110008356-A1 | IL-17 HETEROMERIC RECEPTOR COMPLEX | AMGEN, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100303820-A1 | METHODS OF TREATMENT USING IL-17E ANTAGONISTS | AMGEN INC. (US) | 2010-12-02 | — | — | US | disclosed |
| CN-101903025-A | Utilize benzopyrone-type PARP inhibitor for treating method for cancer and compositions | BIPAR SCIENCES INC | 2010-12-01 | — | — | CN | disclosed |
| US-20100297668-A1 | HUMAN E3ALPHA UBIQUITIN LIGASE FAMILY | AMGEN INC. (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2250200-A2 | IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF | AMGEN INC. (US) | 2010-11-17 | — | — | EP | disclosed |
| CN-101889022-A | Trimeric IL-1Ra | ANAPHORE INC | 2010-11-17 | — | — | CN | disclosed |
| US-7833527-B2 | Using cytokine receptor specific immunoglobulin as therapeutic tool in treatment and prevention of inflammatory, nervous system, skin and autoimmune disorders | AMGEN INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7811791-B2 | Interferon-like molecules and uses thereof | AMGEN INC. (US) | 2010-10-12 | — | — | US | disclosed |
| CN-101848704-A | Techniques for preparing microparticles | NEXBIO INC | 2010-09-29 | — | — | CN | disclosed |
| US-7790674-B2 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2010097410-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | RESPIRATORIUS AB (SE) | 2010-09-02 | — | — | WO | disclosed |
| US-7786284-B2 | Expression vector comprising nucleotide sequences coding cytokine receptor specific immunoglobulin for treatment and prevention of inflammation, cartilage degradation and bone resorption | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-2214748-A1 | SELF-ELIMINATING COATINGS | Interface Biologics Inc. (CA) | 2010-08-11 | — | — | EP | disclosed |
| EP-2203498-A1 | OLIGOFLUORINATED CROSS-LINKED POLYMERS AND USES THEREOF | Interface Biologics Inc. (CA) | 2010-07-07 | — | — | EP | disclosed |
| US-20100166874-A1 | Technology for Preparation of Macromolecular Microspheres | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-01 | — | — | US | disclosed |
| US-7745586-B2 | Human E3α ubiquitin ligase family | AMGEN INC. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2195337-A1 | TRIMERIC IL-1RA | Anaphore, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| US-7732587-B2 | Nucleic acids encoding truncated soluble tumor necrosis factor | AMGEN INC. (US) | 2010-06-08 | — | — | US | disclosed |
| WO-2010042243-A1 | TETRANECTIN TRIMERI ZING MODULE TRUNCATION VARIANTS | ANAPHORE, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| EP-2173327-A2 | TECHNOLOGY FOR THE PREPARATION OF MICROPARTICLES | Nexbio, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| EP-2170958-A1 | IL-17 HETEROMERIC RECEPTOR COMPLEX | Amgen Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100055068-A1 | GRAFTED POLYMERS AND USES THEREOF | INTERFACE BIOLOGICS INCORPORATED (CA) | 2010-03-04 | — | — | US | disclosed |
| US-20100048520-A1 | RIFAXIMIN ANTI-RECTAL DYSFUNCTION PREPARATION | SALIX PHARMACEUTICALS, LTD. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7666839-B2 | Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666831-B2 | Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666832-B2 | Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20100041771-A1 | Bioreponsive Polymers | INTERFACE BIOLOGICS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100034862-A1 | COVALENTLY GRAFTED PHARMACEUTICALLY ACTIVE POLYMERS | INTERFACE BIOLOGICS, INC. (CA) | 2010-02-11 | — | — | US | disclosed |
| US-7658924-B2 | Angiopoietin-2 specific binding agents | AMGEN INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20100028995-A1 | Tetranectin Trimerizing Polypeptides | ANAPHORE, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100028345-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2144928-A2 | JACQUELINIDENTIFICATION AND METHOD FOR USING THE PRE-LIGAND ASSEMBLY DOMAIN OF THE IL-17 RECEPTOR | Amgen Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090325880-A1 | TNF RECEPTOR-LIKE MOLECULES AND USES THEREOF | AMGEN INC. | 2009-12-31 | — | — | US | disclosed |
| EP-2117513-A2 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | Carbylan Biosurgery, Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-0904112-B1 | COMPOSITION COMPRISING IL-1RA AS INTERLEUKIN-1 INHIBITOR AND HYALURONAN AS CONTROLLED RELEASE POLYMER | AMGEN INC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20090281287-A1 | IL-17 receptor like molecules and uses thereof | AMGEN INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009136976-A2 | IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF | AMGEN INC (US) | 2009-11-12 | — | — | WO | disclosed |
| US-7611857-B2 | Identifying a modulator of IL-17 receptor-like polypeptide activity; drug screening; treating inflammation | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| WO-2009129630-A1 | COVALENTLY GRAFTED PHARMACEUTICALLY ACTIVE POLYMERS | INTERFACE BIOLOGICS INC. (CA) | 2009-10-29 | — | — | WO | disclosed |
| CN-101541833-A | IL-17 receptor A antigen binding proteins | AMGEN INC (US) | 2009-09-23 | — | — | CN | disclosed |
| US-20090232799-A1 | Antibodies that bind urokinase-type plasminogen activator and epitopes therefor | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090203609-A1 | Use of IL-1 inhibitors for treating IL-1 mediated diseases | AMGEN INC. | 2009-08-13 | — | — | US | disclosed |
| US-7569387-B2 | Specifically binds an MK61 polypeptide produced by immunizing an animal | AMGEN INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20090191212-A1 | Angiopoietin-2 Specific Binding Agents | AMGEN, INC. | 2009-07-30 | — | — | US | disclosed |
| EP-2076541-A2 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | Amgen Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090143276-A1 | Trimeric IL-1Ra | ANAPHORE, INC. | 2009-06-04 | — | — | US | disclosed |
| EP-1317536-B1 | TNF RECEPTOR-LIKE MOLECULES AND USES THEREOF | AMGEN INC (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20090117059-A1 | COMPOSITIONS AND METHODS OF USE THEREOF, FOR THE TREATMENT OF ORAL PAIN, COMPRISING CLOVES OR EXTRACTS THEREOF IN COMBINATION WITH A STEROID | XVASIVE, INC. | 2009-05-07 | — | — | US | disclosed |
| WO-2009049426-A1 | SELF-ELIMINATING COATINGS | INTERFACE BIOLOGICS INC. (CA) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099078-A1 | Nogo Receptor Antagonists | BIOGEN IDEC MA INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090098207-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098575-A1 | The Human E3alpha Ubiquitin Ligase Family | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009048961-A1 | TRIMERIC IL-1RA | ANAPHORE, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009043174-A1 | OLIGOFLUORINATED CROSS-LINKED POLYMERS AND USES THEREOF | INTERFACE BIOLOGICS INC. (CA) | 2009-04-09 | — | — | WO | disclosed |
| CN-101404980-A | Preparation Technology of Macromolecular Microspheres | NEXBIO INC (US) | 2009-04-08 | — | — | CN | disclosed |
| EP-2040758-A2 | BIORESPONSIVE POLYMERS | Interface Biologics Inc. (CA) | 2009-04-01 | — | — | EP | disclosed |
| US-20090074758-A1 | IL-17 receptor a antigen binding proteins | AMGEN, INC, (US) | 2009-03-19 | — | — | US | disclosed |
| US-7491500-B2 | Mammalian cytokine; related reagents | SCHERING CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| WO-2009020561-A2 | COMPOSITIONS AND METHODS OF USE THEREOF, FOR THE TREATMENT OF ORAL PAIN, COMPRISING CLOVES OR EXTRACT THEREOF IN COMBINATION WITH A STEROID | XVASIVE INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009015286-A2 | TECHNOLOGY FOR THE PREPARATION OF MICROPARTICLES | NEXBIO, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| EP-2010584-A2 | GRAFTED POLYMERS AND USES THEREOF | Interface Biologics Inc. (CA) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008156709-A1 | IL-17 HETEROMERIC RECEPTOR COMPLEX | AMGEN INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2007089601-A9 | NOGO RECEPTOR ANTAGONISTS | BIOGEN IDEC INC (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-2002846-A2 | Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases | Amgen Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1996710-A2 | RIFAXIMIN ANTI-RECTAL DYSFUNCTION PREPARATION | Salix Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-7449555-B2 | Antibodies of angiogenesis inhibiting domains CD148 | AMGEN INC. (US) | 2008-11-11 | — | — | US | disclosed |
| WO-2008131315-A2 | JACQUELINIDENTIFICATION AND METHOD FOR USING THE PRE-LIGAND ASSEMBLY DOMAIN OF THE IL-17 RECEPTOR | AMGEN INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-0831912-B2 | IMPROVED FORMULATION FOR CONTROLLED RELEASE OF DRUGS BY COMBINING HYDROPHILIC AND HYDROPHOBIC AGENTS | ALLERGAN INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1981483-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | Nexbio, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1981902-A2 | NOGO RECEPTOR ANTAGONISTS | Biogen Idec MA Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080219979-A1 | Using cytokine receptor specific immunoglobulin as therapeutic tool in treatment and prevention of inflammatory, nervous system, skin and autoimmune disorders | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080220479-A1 | Expression vector comprising nucleotide sequences coding cytokine receptor specific immunoglobulin for treatment and prevention of inflammation, cartilage degradation and bone resorption | AMGEN, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-7422847-B2 | Human E3α ubiquitin ligase family | AMGEN INC. (US) | 2008-09-09 | — | — | US | disclosed |
| WO-2008098019-A2 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | CARBYLAN BIOSURGERY, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008054603-A9 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN INC (US) | 2008-07-03 | — | — | WO | disclosed |
| CN-101203250-A | Methods and compositions for the delivery of biologically active agents | INTERFACE BIOLOGICS INC (CA) | 2008-06-18 | — | — | CN | disclosed |
| EP-1750764-A4 | ANTIBODIES OF ANGIOGENESIS INHIBITING DOMAINS OF CD148 | AMGEN INC (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008054603-A2 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008053362-A2 | BIORESPONSIVE POLYMERS | INTERFACE BIOLOGICS, INC. (CA) | 2008-05-08 | — | — | WO | disclosed |
| CN-100376291-C | Porous drug matrices and methods of manufacture thereof | ACUSPHERE INC (US) | 2008-03-26 | — | — | CN | disclosed |
| CN-101124246-A | Antibodies to the angiogenesis inhibitory domain of CD148 | AMGEN INC (US) | 2008-02-13 | — | — | CN | disclosed |
| EP-1240327-B1 | INTERFERON-LIKE MOLECULES AND USES THEREOF | AMGEN INC (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007148230-A2 | GRAFTED POLYMERS AND USES THEREOF | INTERFACE BIOLOGICS INCORPORATED (CA) | 2007-12-27 | — | — | WO | disclosed |
| EP-1868664-A2 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | Interface Biologics Inc. (CA) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007114881-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | NEXBIO, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070231831-A1 | The human E3alpha ubiquitin ligase family | AMGEN INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070231264-A1 | MAMMALIAN CYTOKINE; RELATED REAGENTS | SCHERING CORPORATION (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1051972-B1 | Nitric oxide donor composition and method for treatment of anal disorders | STRAKAN INT LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-20070225221-A1 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2007-09-27 | — | — | US | disclosed |
| WO-2007103448-A2 | RIFAXIMIN ANTI-RECTAL DYSFUNCTION PREPARATION | SALIX PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007095583-A2 | METHODS FOR TREATING CANCER AND SENSITIZING CANCER CELLS USING THE SERINE PROTEASE INHIBITOR, MASPIN | CHILDREN'S MEMORIAL RESEARCH CENTER (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070190163-A1 | Technology for preparation of macromolecular microspheres | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTE OF HEALTH | 2007-08-16 | — | — | US | disclosed |
| WO-2007089601-A2 | NOGO RECEPTOR ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| EP-1814914-A2 | ANTIBODIES THAT BIND UROKINASE-TYPE PLASMINOGEN ACTIVATOR AND EPITOPES THEREFOR | The Regents of the University of Colorado (US) | 2007-08-08 | — | — | EP | disclosed |
| CN-101005828-A | Compositions comprising a mucoadhesive protein and an activeprinciple for mucosal delivery of said agents | VIRUN INC (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1807033-A2 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1805219-A1 | ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS | Amgen, Inc (US) | 2007-07-11 | — | — | EP | disclosed |
| US-7241438-B2 | AK155 polypeptides | SCHERING CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070141089-A1 | Topical composition comprising terbinaf ine adn hydrocortisone | LARNIER CATHERINE | 2007-06-21 | — | — | US | disclosed |
| EP-0914431-B1 | TRUNCATED SOLUBLE TUMOR NECROSIS FACTOR TYPE-I RECEPTORS | AMGEN INC (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20070123459-A1 | IL-17 like molecules and uses thereof | AMGEN INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-7220547-B2 | Human E3α ubiquitin ligase family | AMGEN, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| WO-2007052308-A2 | GLYCO-PHOSPHORYLATED BIOLOGICALLY ACTIVE AGENTS | BRAIN N' BEYOND BIOTECH PVT. LTD. (IN) | 2007-05-10 | — | — | WO | disclosed |
| US-20070093418-A1 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093419-A1 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2007-04-26 | — | — | US | disclosed |
| EP-1777234-A2 | Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2 | Amgen Inc. (US) | 2007-04-25 | — | — | EP | disclosed |
| US-7205275-B2 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1768647-A1 | COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENT | Virun, Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20070072801-A1 | Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
| EP-1767544-A2 | Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2 | Amgen Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070065868-A1 | IL-17 receptor like molecules and uses thereof | AMGEN INC. (US) | 2007-03-22 | — | — | US | disclosed |
| EP-1764370-A2 | Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2 | Amgen Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| US-7189761-B2 | Nitric oxide donor composition and method for treatment of anal disorders | CELLEGY PHARMACEUTICALS, INC. | 2007-03-13 | — | — | US | disclosed |
| US-7179625-B2 | Human E3α ubiquitin ligase family | AMGEN INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070037891-A1 | Methods and compositions for the delivery of biologically active agents | INTERFACE BIOLOGICS (CA) | 2007-02-15 | — | — | US | disclosed |
| EP-1750764-A2 | ANTIBODIES OF ANGIOGENESIS INHIBITING DOMAINS OF CD148 | Amgen Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2007011290-A1 | Bronchorelaxing agents based on indol- and isoquinoline derivatives | RESPIRATORIUS AB (SE) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015219-A1 | TNF receptor-like molecules and uses thereof | AMGEN INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2007004067-A2 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | INTERFACE BIOLOGICS INC. (CA) | 2007-01-11 | — | — | WO | disclosed |
| EP-1740187-A1 | MACULAR EDEMA PATIENT SELECTION METHOD AND TREATMENT WITH EYE IMPLANT COMPRISING A STEROID | Bausch & Lomb Incorporated (US) | 2007-01-10 | — | — | EP | disclosed |
| US-7153669-B2 | Nucleic acids encoding MK61 receptors | AMGEN INC. (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060280774-A1 | Compositions and methods for treating glaucoma | ALLERGAN, INC. (US) | 2006-12-14 | — | — | US | disclosed |
| EP-1727520-A2 | METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS | MEDCRYSTALFORMS, LLC (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1562627-A4 | CORTICOSTEROID CONJUGATES AND USES THEREOF | MCLEAN HOSPITAL CORP (US) | 2006-11-02 | — | — | EP | disclosed |
| US-7122198-B1 | Fast dissolving composition with prolonged sweet taste | PANACEA BIOTEC LIMITED (IN) | 2006-10-17 | — | — | US | disclosed |
| EP-1708999-A1 | BRONCHORELAXING COMPOUNDS | RESPIRATORIUS AB (SE) | 2006-10-11 | — | — | EP | disclosed |
| CN-1823737-A | Porous drug matrices and methods of manufacture thereof | ACUSPHERE INC (US) | 2006-08-30 | — | — | CN | disclosed |
| US-7094566-B2 | IL-17 receptor like molecules and uses thereof | AMGEN INC., (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1656125-A2 | TOPICAL COMPOSITION COMPRISING TERBINAFINE AND HYDROCORTISONE | Novartis Consumer Health S.A. (CH) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006050177-A2 | ANTIBODIES THAT BIND UROKINASE-TYPE PLASMINOGEN ACTIVATOR AND EPITOPES THEREFOR | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006045049-A1 | ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006044206-A2 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060078933-A1 | IL-receptor like molecules and uses thereof | AMGEN INC. (US) | 2006-04-13 | — | — | US | disclosed |
| US-20060078966-A1 | IL-17 receptor like polypeptides and uses thereof | AMGEN INC. (US) | 2006-04-13 | — | — | US | disclosed |
| US-20060078967-A1 | Antibodies for IL-17 receptor like polypeptides and uses thereof | AMGEN INC. (US) | 2006-04-13 | — | — | US | disclosed |
| US-20060078604-A1 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. | 2006-04-13 | — | — | US | disclosed |
| US-7026360-B1 | Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients | INPHARMA S.A. (CH) | 2006-04-11 | — | — | US | disclosed |
| EP-1637164-A2 | Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents | Allergan, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20060040919-A1 | Bronchorelaxing compounds | RESPIRATORIUS AB (SE) | 2006-02-23 | — | — | US | disclosed |
| US-20060034846-A1 | Use of TF antagonists | NOVO NORDISK A/S (DK) | 2006-02-16 | — | — | US | disclosed |
| CN-1240373-C | Porous drug matrices and methods of making same | ACUSPHERE INC (US) | 2006-02-08 | — | — | CN | disclosed |
| US-20060024795-A1 | Interferon-Like molecules and uses thereof | WELCHER ANDREW | 2006-02-02 | — | — | US | disclosed |
| US-20060024267-A1 | TNFr/OPG-like molecules and uses thereof | WELCHER ANDREW A | 2006-02-02 | — | — | US | disclosed |
| US-20060018909-A1 | Angiopoietin-2 specific binding agents | AMGEN INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2006009825-A1 | COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENTS | VIRUN, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-6989147-B2 | Truncated soluble tumor necrosis factor type-I and type-II receptors | AMGEN INC. (US) | 2006-01-24 | — | — | US | disclosed |
| EP-1615952-A2 | METHODS OF TREATMENT OF INFLAMMATORY DISEASES USING SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 | Amgen Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-0831912-B1 | IMPROVED FORMULATION FOR CONTROLLED RELEASE OF DRUGS BY COMBINING HYDROPHILIC AND HYDROPHOBIC AGENTS | ALLERGAN INC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20060002931-A1 | Antibodies of angiogenesis inhibiting domains CD148 | AMGEN INC. (US) | 2006-01-05 | — | — | US | disclosed |
| EP-1021204-B1 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMA (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050281772-A1 | Compositions for mucosal delivery of agents | VIRUN, INC. | 2005-12-22 | — | — | US | disclosed |
| WO-2005117970-A2 | ANTIBODIES OF ANGIOGENESIS INHIBITING DOMAINS OF CD148 | AMGEN, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050250696-A1 | Truncated soluble tumor necrosis factor type-I and type-II receptors | FISHER ERIC F | 2005-11-10 | — | — | US | disclosed |
| WO-2005099717-A1 | MACULAR EDEMA PATIENT SELECTION METHOD AND TREATMENT WITH EYE IMPLANT COMPRISING A STEROID | BAUSCH & LOMB INCORPORATED (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050234221-A1 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC., A DELAWARE CORP. | 2005-10-20 | — | — | US | disclosed |
| US-20050226814-A1 | Diagnostic method and kit for implantation of a sustained release drug-delivery implant with a steroid | BAUSCH & LOMB INCORPORATED | 2005-10-13 | — | — | US | disclosed |
| US-20050221344-A1 | Interferon-Like molecules and uses thereof | WELCHER ANDREW | 2005-10-06 | — | — | US | disclosed |
| US-20050181041-A1 | Method of preparation of mixed phase co-crystals with active agents | MEDCRYSTALFORMS, LLC (US) | 2005-08-18 | — | — | US | disclosed |
| EP-1562627-A2 | CORTICOSTEROID CONJUGATES AND USES THEREOF | The McLean Hospital Corporation (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005070887-A1 | BRONCHORELAXING COMPOUNDS | RESPIRATORIUS AB (SE) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005055983-A2 | METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS | MEDCRYSTALFORMS, LLC (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050123512-A1 | Nucleic encoding interleukin-1 receptor antagonist-like proteins and uses thereof | AMGEN, INC., A CORPORATION OF THE STATE OF DELAWARE | 2005-06-09 | — | — | US | disclosed |
| US-20050089876-A1 | Human E3alpha ubiquitin ligase family | HAN HUI-QUAN (US) | 2005-04-28 | — | — | US | disclosed |
| US-20050075391-A1 | Nitric oxide donor composition and method for treatment of anal disorders | CELLEGY PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-20050074427-A1 | IL-17 like molecules and uses thereof | MEDLOCK EUGENE (US) | 2005-04-07 | — | — | US | disclosed |
| US-20050048029-A1 | Il-17 like molecules and uses thereof | AMGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| WO-2005013955-A2 | TOPICAL COMPOSITION COMPRISING TERBINAFINE AND HYDROCORTISONE | NOVARTIS CONSUMER HEALTH S.A. (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-20050009106-A1 | Mammalian cytokine; related reagents | SCHERING CORPORATION, A NEW JERSEY CORPORATION | 2005-01-13 | — | — | US | disclosed |
| US-20050003451-A1 | IL-17 like molecules and uses thereof | MEDLOCK EUGENE (US) | 2005-01-06 | — | — | US | disclosed |
| CN-1178699-C | Pharmaceutical Compsns. contg. compounds with activity for enhancement of absorption of active ingredients | — | 2004-12-08 | — | — | CN | disclosed |
| EP-1477187-A1 | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents | Allergan, Inc. (US) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004092215-A2 | METHODS OF TREATMENT OF INFLAMMATORY DISEASES USING SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 | AMGEN INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040208872-A1 | Nucleic encoding interleukin-1 receptor antagonist-like proteins and uses thereof | AMGEN, INC., A CORPORATION OF THE STATE OF DELAWARE | 2004-10-21 | — | — | US | disclosed |
| US-6797813-B2 | NUCLEOTIDE SEQUENCES CODING POLYPEPTIDES FOR USE IN THE TREATMENT OF RHEUMATIC AND RHEUMATOID ARTHRITIS | SCHERING CORPORATION | 2004-09-28 | — | — | US | disclosed |
| US-20040185037-A1 | Human E3alpha ubiquitin ligase family | HAN HUI-QUAN (US) | 2004-09-23 | — | — | US | disclosed |
| EP-1456378-A2 | IL-17 LIKE MOLECULES AND USES THEREOF | Amgen Inc. (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040157810-A1 | Corticosteroid conjugates and uses thereof | MCLEAN HOSPITAL CORPORATION, THE | 2004-08-12 | — | — | US | disclosed |
| US-6733753-B2 | ANTIINFLAMMATORY PROTEIN | AMGEN INC. | 2004-05-11 | — | — | US | disclosed |
| US-6706505-B1 | ISOLATED NUCLEIC ACID MOLECULE COMPRISING SPECIFIED NUCLEOTIDE SEQUENCE, NUCLEOTIDE SEQUENCE ENCODING SPECIFIED POLYPEPTIDE, OR NUCLEOTIDE SEQUENCE FULLY COMPLEMENTARY TO EITHER | AMGEN INC | 2004-03-16 | — | — | US | disclosed |
| US-20040047863-A1 | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | AMGEN INC. | 2004-03-11 | — | — | US | disclosed |
| US-20040048799-A1 | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | AMGEN INC. | 2004-03-11 | — | — | US | disclosed |
| US-20040048338-A1 | IL-17 receptor like molecules and uses thereof | JING SHUQIAN (US) | 2004-03-11 | — | — | US | disclosed |
| US-20040044001-A1 | Use of II-1 inhibitors for treating II-1 mediated diseases | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2004017904-A2 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20040023335-A1 | IL-17 like molecules and uses thereof | JING SHUQIAN (US) | 2004-02-05 | — | — | US | disclosed |
| US-20040018241-A1 | Bioadhesive compositions and methods for topical administration of active agents | NOVEN PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| US-20030236193-A1 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. | 2003-12-25 | — | — | US | disclosed |
| US-6638528-B1 | Pressure-sensitive adhesive matrix comprising blend of polyacrylate, polysiloxane, polyisobutylene, polyisoprene, polyamide or polystyrene; and insoluble, non-adhesive ethyl cellulose; polyvinylpyrrolidone crystallization inhibitor | NOVEN PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| EP-1352656-A2 | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | Amgen Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| CN-1121854-C | Transdermal device containing polyvinylpyrrolidone as solubility ehancer | NOVEN PHARMA (US) | 2003-09-24 | — | — | CN | disclosed |
| US-20030166069-A1 | Interleukin-1 receptor antagonist-like molecules and uses thereof | AMGEN, INC. | 2003-09-04 | — | — | US | disclosed |
| US-20030166164-A1 | IL-17 like molecules and uses thereof | AMGEN INC. | 2003-09-04 | — | — | US | disclosed |
| EP-1329225-A2 | Transdermal device containing polyvinylpyrrolidone as solubility enhancer | NOVEN PHARMACEUTICALS, INC. (US) | 2003-07-23 | — | — | EP | disclosed |
| WO-2003055980-A2 | IL-17 LIKE MOLECULES AND USES THEREOF | AMGEN INC. (US) | 2003-07-10 | — | — | WO | disclosed |
| US-20030124092-A1 | IL-17 like molecules and uses thereoflike molecules and uses thereof | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| EP-1317536-A2 | TNF RECEPTOR-LIKE MOLECULES AND USES THEREOF | Amgen Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20030099980-A1 | IL-17 receptor like molecules and uses thereof | JING SHUQIAN (US) | 2003-05-29 | — | — | US | disclosed |
| US-6562363-B1 | Bioadhesive compositions and methods for topical administration of active agents | NOVEN PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| CN-1107499-C | Nitric oxide donor compositions and methods for treating anal disorders | NEPTUNE PHARMACEUTICAL CORP (US) | 2003-05-07 | — | — | CN | disclosed |
| US-20030077246-A1 | TNFr/OPG-like molecules and uses thereof | WELCHER ANDREW A (US) | 2003-04-24 | — | — | US | disclosed |
| US-20030072756-A1 | Combination therapy using an IL-1 inhibitor and methotrexate | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030073199-A1 | Mammalian cytokine; related reagents | SCHERING CORPORATION | 2003-04-17 | — | — | US | disclosed |
| EP-1294765-A2 | IL-17 MOLECULES AND USES THEREOF | Amgen, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20030054439-A1 | Truncated soluble tumor necrosis factor type-I and type-II receptors | AMGEN INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030004106-A1 | Interleukin-1 receptor antagonist-related molecules and uses thereof | AMGEN, INC., A CORPORATION OF THE STATE OF DELAWARE | 2003-01-02 | — | — | US | disclosed |
| WO-2001068859-A9 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1266002-A2 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1255837-A2 | IL-17 LIKE MOLECULES AND USES THEREOF | Amgen Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020161042-A1 | Nitric oxide donor composition and method for treatment of anal disorders | CELLEGY PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020150977-A1 | TNF receptor-like molecules and uses thereof | AMGEN INC. | 2002-10-17 | — | — | US | disclosed |
| EP-1246844-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONIST-RELATED MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020137137-A1 | Interferon-like molecules and uses thereof | AMGEN, INC. | 2002-09-26 | — | — | US | disclosed |
| WO-2002072107-A1 | TOPICAL COMPOSITION CONTAINING HYDROCORTISONE | NOVARTIS CONSUMER HEALTH S.A. (CH) | 2002-09-19 | — | — | WO | disclosed |
| EP-1239870-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONIST-LIKE MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1240197-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONIST-LIKE MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1240327-A2 | INTERFERON-LIKE MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1238077-A1 | TNFR/OPG-LIKE MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-1235561-A2 | FAST DISSOLVING COMPOSITION WITH PROLONGED SWEET TASTE | Panacea Biotec Limited (IN) | 2002-09-04 | — | — | EP | disclosed |
| US-20020119924-A1 | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | AMGEN INC. | 2002-08-29 | — | — | US | disclosed |
| CN-1365274-A | Porous drug matrices and methods of making same | ACUSPHERE INC (US) | 2002-08-21 | — | — | CN | disclosed |
| US-20020049188-A1 | Nitroglycerin ointment for treatment of pain associated with anal disease | CELLEGY PHARMACEUTICALS, INC. | 2002-04-25 | — | — | US | disclosed |
| US-20020045213-A1 | IL-17 receptor like molecules and uses thereof | AMGEN INC., A DELAWARE CORPORATION | 2002-04-18 | — | — | US | disclosed |
| US-6369116-B1 | SUSTAINED RELEASE DEXAMETHASON | OCULEX PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | disclosed |
| US-20020037524-A1 | IL-17 like molecules and uses thereof | AMGEN INC., A DELAWARE CORPORATION | 2002-03-28 | — | — | US | disclosed |
| WO-2002020762-A2 | TNF RECEPTOR-LIKE MOLECULES AND USES THEREOF | AMGEN INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002008285-A2 | IL-17 MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| US-20020009454-A1 | Composition and method for treating inflammatory diseases | AMGEN INC. | 2002-01-24 | — | — | US | disclosed |
| US-20020004065-A1 | Compositions and methods to effect the release profile in the transdermal administration of active agents | KANIOS DAVID (US) | 2002-01-10 | — | — | US | disclosed |
| US-6306820-B1 | FAS ANTIGEN; RHEUMATIC DISEASES, ANTIINFLAMMATORY AGENTS; SEPTIC SHOCK PREVENTION | AMGEN INC. | 2001-10-23 | — | — | US | disclosed |
| US-20010025057-A1 | Nitric oxide donor composition and method for treatment of anal disorders | CELLEGY PHARMACEUTICALS, INC. | 2001-09-27 | — | — | US | disclosed |
| US-6294170-B1 | PROTEINACEOUS IL-1 INHIBITOR (INTERLEUKIN-1RA) BY EXTENDED DELIVERY MEANS, E.G., CONTROLLED RELEASE POLYMER FORMULATIONS (HYALURONAN), IL-1RA FUSION PROTEINS AND CHEMICAL ATTACHMENT, AND CONTINUOUS PUMP INFUSION, ARTHRITIS, FUSION PROTEIN | AMGEN INC. | 2001-09-25 | — | — | US | disclosed |
| WO-2001068859-A2 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC. (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001059120-A2 | IL-17 LIKE MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| WO-2001044472-A1 | TNFR/OPG-LIKE MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001043735-A1 | NITROGLYCERIN OINTMENT FOR TREATMENT OF PAIN ASSOCIATED WITH ANAL DISEASE | CELLEGY PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001042304-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONIST-RELATED MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001042305-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONIST-LIKE MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001041792-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONIST-LIKE MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001042474-A2 | INTERFERON-LIKE MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001039749-A2 | FAST DISSOLVING COMPOSITION WITH PROLONGED SWEET TASTE | PANACEA BIOTEC LIMITED (IN) | 2001-06-07 | — | — | WO | disclosed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | disclosed |
| US-6221383-B1 | BLEND OF AT LEAST TWO POLYMERS, OR AT LEAST ONE POLYMER AND A SOLUBLE POLYVINYLPYRROLIDONE, IN COMBINATION WITH A DRUG PROVIDES A PRESSURE-SENSITIVE ADHESIVE COMPOSITION FOR A TRANSDERMAL DRUG DELIVERY SYSTEM | NOVEN PHARMACEUTICALS, INC. | 2001-04-24 | — | — | US | disclosed |
| EP-1051972-A1 | Nitric oxide donor composition and method for treatment of anal disorders | Cellegy Pharmaceuticals, Inc (US) | 2000-11-15 | — | — | EP | disclosed |
| EP-0719145-B1 | NITRIC OXIDE DONOR COMPOSITION FOR TREATMENT OF ANAL DISORDERS | CELLEGY PHARMA INC (US) | 2000-09-06 | — | — | EP | disclosed |
| US-6096728-A | Composition and method for treating inflammatory diseases | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-1021204-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6024976-A | TRANSDERMAL DRUG DELIVERY WITH PRESSURE SENSITIVE ADHESIVE COMPOSITION OF POLYVINYLPYRROLIDONE WITH DRUG IN MULTILAYER PATCH | NOVEN PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| CN-1240479-A | Truncated soluble tumor necrosis factor type-I and type-II receptors | AMGEN INC (US) | 2000-01-05 | — | — | CN | disclosed |
| EP-0949931-A1 | COMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TREATING IL-1 MEDIATED DISEASES | AMGEN INC. (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0942740-A2 | COMBINATION THERAPY USING A TNF BINDING PROTEIN FOR TREATING TNF-MEDIATED DISEASES | AMGEN INC. (US) | 1999-09-22 | — | — | EP | disclosed |
| EP-0914431-A2 | TRUNCATED SOLUBLE TUMOR NECROSIS FACTOR TYPE-I AND TYPE-II RECEPTORS | AMGEN INC. (US) | 1999-05-12 | — | — | EP | disclosed |
| CN-1215340-A | Composition comprising interleukin-1 inhibitor and controlled release polymer | AMGEN BULDER INC (US) | 1999-04-28 | — | — | CN | disclosed |
| WO-1999015210-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| EP-0904112-A1 | COMPOSITION COMPRISING INTERLEUKIN-1 INHIBITOR AND CONTROLLED RELEASE POLYMER | Amgen Inc., (US) | 1999-03-31 | — | — | EP | disclosed |
| EP-0786999-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0719145-A4 | NITRIC OXIDE DONOR COMPOSITION AND METHOD FOR TREATMENT OF ANAL DISORDERS | CELLEGY PHARMA INC (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0792371-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | disclosed |
| US-5837698-A | DERIVATIVES OF BETA-METHASONE, DEXAMETHASONE, BUDESONIDE AND TRIAMCINOLOLE WITH NITRATE | G. D. SEARLE & CO. (US) | 1998-11-17 | — | — | US | disclosed |
| WO-1998024463-A2 | COMBINATION THERAPY USING A TNF BINDING PROTEIN FOR TREATING TNF-MEDIATED DISEASES | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024477-A1 | COMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TREATING IL-1 MEDIATED DISEASES | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | disclosed |
| US-5719197-A | DRUG DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| WO-1998001555-A2 | TRUNCATED SOLUBLE TUMOR NECROSIS FACTOR TYPE-I AND TYPE-II RECEPTORS | AMGEN INC. (US) | 1998-01-15 | — | — | WO | disclosed |
| US-5693676-A | USING NITROGLYCERIN TO TREAT ANAL FISSURES OR ULCERS, HEMORRHOIDS, LEVATOR SPASMS | NEPTUNE PHARMACEUTICAL CORPORATION (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1997028828-A1 | COMPOSITION COMPRISING INTERLEUKIN-1 INHIBITOR AND CONTROLLED RELEASE POLYMER | AMGEN BOULDER INC. (US) | 1997-08-14 | — | — | WO | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | disclosed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | disclosed |
| CN-1143318-A | Transdermal device containing polyvinylpyrrolidone as dissolution enhancer | NOVEN PHARMA (US) | 1997-02-19 | — | — | CN | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| CN-1137748-A | Gas used as local and subcutaneous transmission carrier and microspheres filled with gas precursor | IMARX PHARMACEUTICAL CORP (US) | 1996-12-11 | — | — | CN | disclosed |
| CN-1131392-A | Nitric oxide donor composition and method for treatment of anal disorders | NEPTUNE PHARMACEUTICAL CORP (US) | 1996-09-18 | — | — | CN | disclosed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | disclosed |
| EP-0719145-A1 | NITRIC OXIDE DONOR COMPOSITION AND METHOD FOR TREATMENT OF ANAL DISORDERS | NEPTUNE PHARMACEUTICAL CORPORATION (US) | 1996-07-03 | — | — | EP | disclosed |
| CN-1125394-A | Novel therapeutic drug delivery system | IMARX PHARMACEUTICAL CORP (US) | 1996-06-26 | — | — | CN | disclosed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1995032715-A1 | NITRIC OXIDE DONOR COMPOSITION AND METHOD FOR TREATMENT OF ANAL DISORDERS | NEPTUNE PHARMACEUTICAL CORPORATION (US) | 1995-12-07 | — | — | WO | disclosed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-5183815-A | Bone acting agents | MERCK & CO., INC. (US) | 1993-02-02 | — | — | US | disclosed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | disclosed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (42 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002278-A1 | Pharmaceutical Compositions for Rectal Administration | SI, CROCC, FABP2 | HIF1A 2920/4885HSD17B10 775/4885NR3C1 2479/4885 |
| US-20110166331-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL2RA | HIF1A 646/4885HSD17B10 812/4885NR3C1 558/4885 |
| US-20140227266-A1 | NOGO Receptor Antagonists | NGFR, RTN4, SRPRB | HIF1A 4095/4885HSD17B10 4752/4885NR3C1 815/4885 |
| US-20100041771-A1 | Bioreponsive Polymers | PEPD, PREP, DNPEP | HIF1A 1886/4885HSD17B10 1213/4885NR3C1 4835/4885 |
| US-20120308566-A1 | USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL23R, IL15RA, IL2RA | HIF1A 1951/4885HSD17B10 3022/4885NR3C1 1188/4885 |
| US-20160159878-A1 | NOGO Receptor Antagonists | NGFR, RTN4, SRPRB | HIF1A 4095/4885HSD17B10 4752/4885NR3C1 815/4885 |
| US-20040044001-A1 | Use of II-1 inhibitors for treating II-1 mediated diseases | IL1A, IL1B, IL1R1 | HIF1A 312/4885HSD17B10 3162/4885NR3C1 1109/4885 |
| US-20100028345-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL15RA | HIF1A 1211/4885HSD17B10 2217/4885NR3C1 1158/4885 |
| US-20040157810-A1 | Corticosteroid conjugates and uses thereof | NR3C1, NR3C2, C3AR1 | HIF1A 4459/4885HSD17B10 237/4885NR3C1 1/4885 |
| US-20100048520-A1 | RIFAXIMIN ANTI-RECTAL DYSFUNCTION PREPARATION | RDX, VIP, RXFP1 | HIF1A 1848/4885HSD17B10 420/4885NR3C1 1019/4885 |
| US-20090203609-A1 | Use of IL-1 inhibitors for treating IL-1 mediated diseases | IL1A, IL1B, IL1R1 | HIF1A 505/4885HSD17B10 3391/4885NR3C1 764/4885 |
| US-20130202654-A1 | Topical Foam Composition | LPXN, RFTN1, RDX | HIF1A 2738/4885HSD17B10 1217/4885NR3C1 727/4885 |
| US-20040048799-A1 | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | TNF, TNFRSF1A, TNFSF11 | HIF1A 2997/4885HSD17B10 4394/4885NR3C1 1060/4885 |
| US-20130315988-A1 | Pharmaceutical Composition | RIF1, MRPL21, MRPS35 | HIF1A 4205/4885HSD17B10 1077/4885NR3C1 2114/4885 |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | CHRM3, ADRB1, ADRB3 | HIF1A 907/4885HSD17B10 535/4885NR3C1 394/4885 |
| US-10208122-B2 | IL-17 receptor A antigen binding proteins | IL17A, IL2RA, IL23R | HIF1A 1992/4885HSD17B10 1128/4885NR3C1 917/4885 |
| US-20020119924-A1 | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | TNF, TNFRSF1A, TNFSF11 | HIF1A 2997/4885HSD17B10 4394/4885NR3C1 1060/4885 |
| US-20140356355-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL15RA | HIF1A 1211/4885HSD17B10 2217/4885NR3C1 1158/4885 |
| US-20100055068-A1 | GRAFTED POLYMERS AND USES THEREOF | ALG1, CD44, PGF | HIF1A 1896/4885HSD17B10 2390/4885NR3C1 3439/4885 |
| US-20120251547-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL15RA | HIF1A 1211/4885HSD17B10 2217/4885NR3C1 1158/4885 |
| US-20220040385-A1 | LOCAL DELIVERY OF DRUGS FROM SELF ASSEMBLED COATINGS | OGFR, F7, F13B | HIF1A 2180/4885HSD17B10 1857/4885NR3C1 2409/4885 |
| US-20200362045-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL15RA | HIF1A 1211/4885HSD17B10 2217/4885NR3C1 1158/4885 |
| US-20040047863-A1 | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | TNF, TNFRSF1A, TNFSF11 | HIF1A 3116/4885HSD17B10 4361/4885NR3C1 1144/4885 |
| US-20060040919-A1 | Bronchorelaxing compounds | CHRM3, GPR3, CHRM2 | HIF1A 3029/4885HSD17B10 212/4885NR3C1 33/4885 |
| US-20110091508-A1 | OLIGOFLUORINATED CROSS-LINKED POLYMERS AND USES THEREOF | MACF1, PUF60, PFAS | HIF1A 1204/4885HSD17B10 4082/4885NR3C1 4605/4885 |
| US-20180042996-A1 | Hydrogel-Linked IL-1ra Prodrug | IL1A, IL1B, IL1R1 | HIF1A 159/4885HSD17B10 1659/4885NR3C1 368/4885 |
| US-20160251443-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL15RA | HIF1A 1211/4885HSD17B10 2217/4885NR3C1 1158/4885 |
| US-20110104228-A1 | SELF-ELIMINATING COATINGS | CD44, MMP20, MMP1 | HIF1A 658/4885HSD17B10 3567/4885NR3C1 3647/4885 |
| US-11858999-B2 | IL-17 receptor A antigen binding proteins | IL17A, IL23R, IL15RA | HIF1A 1211/4885HSD17B10 2217/4885NR3C1 1158/4885 |
| US-20080220479-A1 | Expression vector comprising nucleotide sequences coding cytokine receptor specific immunoglobulin for treatment and prevention of inflammation, cartilage degradation and bone resorption | NGFR, IL17A, IL15RA | HIF1A 1749/4885HSD17B10 2584/4885NR3C1 737/4885 |
| US-20110008841-A1 | POLYNUCLEOTIDES ENCODING IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL23R, IL15RA, IL17A | HIF1A 2938/4885HSD17B10 2888/4885NR3C1 1054/4885 |
| US-20030072756-A1 | Combination therapy using an IL-1 inhibitor and methotrexate | IL1A, IL1B, IL1RN | HIF1A 983/4885HSD17B10 3271/4885NR3C1 695/4885 |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | NR3C1, NR3C2, C3AR1 | HIF1A 4459/4885HSD17B10 237/4885NR3C1 1/4885 |
| US-20190262426-A1 | Hydrogel-Linked IL-1ra Prodrug | IL1A, IL1R1, IL1B | HIF1A 139/4885HSD17B10 1455/4885NR3C1 756/4885 |
| US-20130142834-A1 | LOCAL DELIVERY OF DRUGS FROM SELF ASSEMBLED COATINGS | OGFR, F13B, F7 | HIF1A 1890/4885HSD17B10 2048/4885NR3C1 2159/4885 |
| US-20190298889-A1 | LOCAL DELIVERY OF DRUGS FROM SELF ASSEMBLED COATINGS | OGFR, F7, F13B | HIF1A 2180/4885HSD17B10 1857/4885NR3C1 2409/4885 |
| US-20110033540-A1 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | BMP2, BMP6, BMP4 | HIF1A 874/4885HSD17B10 2214/4885NR3C1 4527/4885 |
| US-10195311-B2 | Local delivery of drugs from self assembled coatings | OGFR, F7, F13B | HIF1A 2180/4885HSD17B10 1857/4885NR3C1 2409/4885 |
| US-11180564-B2 | IL-17 Receptor A antigen binding proteins | IL17A, IL23R, IL15RA | HIF1A 1211/4885HSD17B10 2217/4885NR3C1 1158/4885 |
| US-20240294652-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL15RA | HIF1A 1211/4885HSD17B10 2217/4885NR3C1 1158/4885 |
| US-20090074758-A1 | IL-17 receptor a antigen binding proteins | IL17A, IL23R, IL2RA | HIF1A 646/4885HSD17B10 812/4885NR3C1 558/4885 |
| US-20100034862-A1 | COVALENTLY GRAFTED PHARMACEUTICALLY ACTIVE POLYMERS | TIE1, TEK, FLT1 | HIF1A 593/4885HSD17B10 3307/4885NR3C1 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.